A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of AGA2118 in Healthy Japanese, Chinese, and Caucasian Participants
Latest Information Update: 03 Feb 2026
At a glance
- Drugs AGA 2118 (Primary)
- Indications Osteoporosis
- Focus Pharmacokinetics
- Acronyms ATLAS
- Sponsors Angitia Biopharmaceuticals
Most Recent Events
- 03 Feb 2026 New trial record